Circulating biomarkers for cardiovascular diseases: the beats never stop

Xi, Lei; Kouvelos, George; Paolocci, Nazareno

doi:10.1038/aps.2018.43

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomarkers are objectively measured characteristics that can be used as indicators of normal biological or pathogenic processes [88] and may be useful for improving diagnosis, prognosis and risk stratification of cardiovascular diseases, including some genetic conditions [89][90][91][92][93][94][95]. A recent study established the upper reference limit (URL) of Gal-3 in a population of healthy subjects, identifying age as an important biological variable that affects Gal-3 concentration, suggesting multiple diagnostic cut-offs related to the different age groups [96].…”

Section: Galectin-3 As a Circulating Markermentioning

confidence: 99%

Galectin-3 in Cardiovascular Diseases

Blanda

Bracale

Taranto

et al. 2020

IJMS

125

View full text Add to dashboard Cite

Galectin-3 (Gal-3) is a β-galactoside-binding protein belonging to the lectin family with pleiotropic regulatory activities and several physiological cellular functions, such as cellular growth, proliferation, apoptosis, differentiation, cellular adhesion, and tissue repair. Inflammation, tissue fibrosis and angiogenesis are the main processes in which Gal-3 is involved. It is implicated in the pathogenesis of several diseases, including organ fibrosis, chronic inflammation, cancer, atherosclerosis and other cardiovascular diseases (CVDs). This review aims to explore the connections of Gal-3 with cardiovascular diseases since they represent a major cause of morbidity and mortality. We herein discuss the evidence on the pro-inflammatory role of Gal-3 in the atherogenic process as well as the association with plaque features linked to lesion stability. We report the biological role and molecular mechanisms of Gal-3 in other CVDs, highlighting its involvement in the development of cardiac fibrosis and impaired myocardium remodelling, resulting in heart failure and atrial fibrillation. The role of Gal-3 as a prognostic marker of heart failure is described together with possible diagnostic applications to other CVDs. Finally, we report the tentative use of Gal-3 inhibition as a therapeutic approach to prevent cardiac inflammation and fibrosis.

show abstract

Section: Galectin-3 As a Circulating Markermentioning

confidence: 99%

Galectin-3 in Cardiovascular Diseases

Blanda

Bracale

Taranto

et al. 2020

IJMS

125

View full text Add to dashboard Cite

show abstract

“…Furthermore, predictive biomarkers of NASH are lacking, resulting in invasive biopsy as the only method for diagnosis ( 51 ). Established biomarkers for CVD including C-reactive protein (CRP), cardiac troponins I and T, B-type natriuretic peptides, and D-dimer, are widely used for diagnosis and management of various CVDs including atherosclerosis, myocardial infarction, acute coronary syndrome, cardiac arrest, thrombosis, and ischemic cardiac diseases ( 142 – 144 ). Despite the wide use of these biomarkers for diagnosis and monitoring, there remains a need to identify new pathological pathways and pertinent biomarkers that can be useful for concurrent diagnosis and monitoring of NAFLD and CVD.…”

Section: Emerging Biomarkers Linking Nafld/nash and Ascvd Offer Poten...mentioning

confidence: 99%

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease

Finney

Das

Kumar

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Therapeutic approaches that lower circulating low-density lipoprotein (LDL)-cholesterol significantly reduced the burden of cardiovascular disease over the last decades. However, the persistent rise in the obesity epidemic is beginning to reverse this decline. Alongside obesity, the incidence of nonalcoholic fatty liver disease (NAFLD) has substantially increased in the last three decades. Currently, approximately one third of world population is affected by NAFLD. Notably, the presence of NAFLD and particularly its more severe form, nonalcoholic steatohepatitis (NASH), serves as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), thus, raising interest in the relationship between these two diseases. Importantly, ASCVD is the major cause of death in patients with NASH independent of traditional risk factors. Nevertheless, the pathophysiology linking NAFLD/NASH with ASCVD remains poorly understood. While dyslipidemia is a common risk factor underlying both diseases, therapies that lower circulating LDL-cholesterol are largely ineffective against NASH. While there are no approved pharmacological therapies for NASH, some of the most advanced drug candidates exacerbate atherogenic dyslipidemia, raising concerns regarding their adverse cardiovascular consequences. In this review, we address current gaps in our understanding of the mechanisms linking NAFLD/NASH and ASCVD, explore strategies to simultaneously model these diseases, evaluate emerging biomarkers that may be useful to diagnose the presence of both diseases, and discuss investigational approaches and ongoing clinical trials that potentially target both diseases.

show abstract